Jason Harris

Articles

Cancer Research May Help Treatment of Severe COVID-19

November 12, 2020

An immunologist and oncologist, Merad has spent her career studying inflammation in patients with cancer and was at the right place at the right time to translate her expertise to examine inflammation in patients with COVID-19.

Start Sexual Health Discussions Early On, Says Expert

October 10, 2020

Maintaining sexual function is often low on the list of priorities for a woman recently diagnosed with a gynecologic cancer, but raising the subject early in her treatment course may make the patient more willing to engage in a discussion as her care progresses, according to Don S. Dizon, MD, who specializes in survivorship issues.

Talazoparib Improves Quality of Life, Not Survival in Advanced Breast Cancer

April 28, 2020

Treatment with talazoparib (Talzenna) did not demonstrate a statistically significant overall survival (OS) benefit in patients with BRCA1/2-mutated metastatic HER2-negative breast cancer, according to updated findings from the phase 3 EMBRACA trial (NCT01945775).1 However, lead author Jennifer Litton, MD, said that there is still reason to believe treatment with the PARP inhibitor can improve OS.

SITC Updates Immunotherapy Guidelines for Melanoma

November 28, 2018

Rapid changes in the treatment landscape for melanoma have prompted the Society for Immunotherapy of Cancer (SITC) to issue updated consensus guidelines to help clinicians stratify patients, choose optimal treatment regimens, and manage immune-related adverse events (irAEs) in patients with stage II to IV disease.

Immunotherapy Pioneers Win Nobel Prize for Research on Checkpoint Inhibitors

October 04, 2018

Immunotherapy pioneers James P. Allison, PhD, and Tasuku Honjo, MD, PhD, have won the 2018 Nobel Prize in Physiology or Medicine for their research that eventually led to the use of immune checkpoint inhibitors to treat cancer.

Published Results Confirm Regorafenib Safety, Efficacy in mCRC

September 25, 2018

Safety and efficacy findings for regorafenib (Stivarga) in patients with previously treated metastatic colorectal cancer (mCRC) were consistent with previous phase III results, according to findings from the phase IIIb CONSIGN trial.